MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis
- 14 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (9), 4732-4748
- https://doi.org/10.1021/acs.jmedchem.0c00003
Abstract
Screening of a GSK-proprietary library against intracellular Mycobacterium tuberculosis identified 1, a thioalkylbenzoxazole hit. Biological profiling and mutant analysis revealed that this compound is a prodrug that is bioactivated by the mycobacterial enzyme MymA. A hit-expansion program including design, synthesis, and profiling of a defined set of analogues with optimized drug-like properties led to the identification of an emerging lead compound, displaying potency against intracellular bacteria in the low micromolar range, high in vitro solubility and permeability, and excellent microsomal stability.Funding Information
- Canadian Institutes of Health Research (PJT-148646)
- Seventh Framework Programme (291799)
- Tres Cantos Open Lab Foundation (TC188)
This publication has 22 references indexed in Scilit:
- Hit Generation in TB Drug Discovery: From Genome to GranulomaChemical Reviews, 2018
- TuberculosisNature Reviews Disease Primers, 2016
- New Era of TB Drug Discovery and Its Impact on Disease ManagementCurrent Treatment Options in Infectious Diseases, 2016
- New agents for the treatment of drug-resistant Mycobacterium tuberculosisAdvanced Drug Delivery Reviews, 2016
- Development of an Intracellular Screen for New Compounds Able To Inhibit Mycobacterium tuberculosis Growth in Human MacrophagesAntimicrobial Agents and Chemotherapy, 2016
- The association between sterilizing activity and drug distribution into tuberculosis lesionsNature Medicine, 2015
- The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cellsNature Reviews Microbiology, 2014
- Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticityDrug Discovery Today, 2011
- The challenge of new drug discovery for tuberculosisNature, 2011
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006